Literature DB >> 22669616

Vascular density and endothelial cell expression of integrin alpha v beta 3 and E-selectin in murine tumours.

Johanne Seguin1, Céline Nicolazzi, Nathalie Mignet, Daniel Scherman, Guy G Chabot.   

Abstract

The endothelial cell adhesion molecules, including the integrin alpha v beta 3 (αvβ3) and E-selectin, are involved in the process of angiogenesis required for tumour growth, cell migration and metastasis. The purpose of this study was to assess and compare widely used tumour models to select the ones most suitable for angiogenesis research. Fifteen murine tumours were selected including melanoma (B16), colon (C26, C38, C51), mammary (MA13, MA16, MA16/Adr, MA17, MA17/Adr, MA25, MA44), pancreatic (PO2, PO3), Glasgow osteogenic sarcoma (GOS) and Lewis lung carcinoma (LLC). The tumour vascular density, assessed using the platelet endothelial cell adhesion molecule 1 (PECAM-1; CD31) immunostaining, revealed that B16 melanoma was poorly vascularized (<5 %), whereas the colon and mammary tumours were well vascularized (5-15 %). The most vascularized tumours (>15 %) were the pancreatic tumours (PO2 and PO3), the sarcoma (GOS) and the lung tumour (LLC). The integrin αvβ3 and E-selectin, evaluated by immunohistology, showed that 7/15 tumours expressed the αvβ3 integrin which was homogeneously distributed on all tumour sections (B16, C26, MA17/Adr, MA25, MA44, PO2, LLC). E-selectin was expressed in 4/15 tumours and its expression was restricted to the tumour periphery. Only 2/15 tumours (B16 and C26) were shown to express both integrin αvβ3 and E-selectin. In conclusion, these data not only contribute to a better understanding of the tumour biology of murine tumours but can also guide the choice of appropriate models for antiangiogenic therapy, for selective drug delivery to tumours and the validation of tumour imaging modalities targeting these endothelial cell adhesion molecules.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22669616      PMCID: PMC3743742          DOI: 10.1007/s13277-012-0428-x

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  58 in total

Review 1.  The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.

Authors:  B P Eliceiri; D A Cheresh
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

Review 2.  Adhesion molecules and gene transfer.

Authors:  R J Parkes; S L Hart
Journal:  Adv Drug Deliv Rev       Date:  2000-11-15       Impact factor: 15.470

Review 3.  Conditional gene targeting for cancer gene therapy.

Authors:  Y S Haviv; D T Curiel
Journal:  Adv Drug Deliv Rev       Date:  2001-12-17       Impact factor: 15.470

4.  The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis.

Authors:  Donald R Senger; Carole A Perruzzi; Michael Streit; Victor E Koteliansky; Antonin R de Fougerolles; Michael Detmar
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

5.  Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3.

Authors:  J C Gutheil; T N Campbell; P R Pierce; J D Watkins; W D Huse; D J Bodkin; D A Cheresh
Journal:  Clin Cancer Res       Date:  2000-08       Impact factor: 12.531

6.  Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.

Authors:  C C Kumar; M Malkowski; Z Yin; E Tanghetti; B Yaremko; T Nechuta; J Varner; M Liu; E M Smith; B Neustadt; M Presta; L Armstrong
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

Review 7.  Inhibitors of integrins.

Authors:  Gordon C Tucker
Journal:  Curr Opin Pharmacol       Date:  2002-08       Impact factor: 5.547

8.  E-selectin is present in proliferating endothelial cells in human hemangiomas.

Authors:  B M Kräling; M J Razon; L M Boon; D Zurakowski; C Seachord; R P Darveau; J B Mulliken; C L Corless; J Bischoff
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

9.  Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice.

Authors:  T H Corbett; B J Roberts; W R Leopold; J C Peckham; L J Wilkoff; D P Griswold; F M Schabel
Journal:  Cancer Res       Date:  1984-02       Impact factor: 12.701

10.  Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases.

Authors:  M Friedlander; C L Theesfeld; M Sugita; M Fruttiger; M A Thomas; S Chang; D A Cheresh
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

View more
  12 in total

Review 1.  Focus on Fundamentals: Achieving Effective Nanoparticle Targeting.

Authors:  Gregory T Tietjen; Laura G Bracaglia; W Mark Saltzman; Jordan S Pober
Journal:  Trends Mol Med       Date:  2018-06-05       Impact factor: 11.951

2.  In Vivo Evaluation of Magnetic Targeting in Mice Colon Tumors with Ultra-Magnetic Liposomes Monitored by MRI.

Authors:  Caroline J Thébault; Grégory Ramniceanu; Aude Michel; Claire Beauvineau; Christian Girard; Johanne Seguin; Nathalie Mignet; Christine Ménager; Bich-Thuy Doan
Journal:  Mol Imaging Biol       Date:  2019-04       Impact factor: 3.488

3.  Comparison of [99mTc]3PRGD2 Imaging and [18F]FDG PET/CT in Breast Cancer and Expression of Integrin αvβ3 in Breast Cancer Vascular Endothelial Cells.

Authors:  Zhenying Chen; Fangmeng Fu; Fang Li; Zhaohui Zhu; Yinghong Yang; Xiangjin Chen; Bing Jia; Shan Zheng; Chao Huang; Weibing Miao
Journal:  Mol Imaging Biol       Date:  2018-10       Impact factor: 3.488

4.  Targeted Delivery of DNA Topoisomerase Inhibitor SN38 to Intracranial Tumors of Glioblastoma Using Sub-5 Ultrafine Iron Oxide Nanoparticles.

Authors:  Yuancheng Li; Manman Xie; Joshua B Jones; Zhaobin Zhang; Zi Wang; Tu Dang; Xinyu Wang; Malgorzata Lipowska; Hui Mao
Journal:  Adv Healthc Mater       Date:  2022-05-06       Impact factor: 11.092

Review 5.  Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment.

Authors:  J David Peske; Amber B Woods; Victor H Engelhard
Journal:  Adv Cancer Res       Date:  2015-06-01       Impact factor: 6.242

6.  Evaluation of Nonradiative Clinical Imaging Techniques for the Longitudinal Assessment of Tumour Growth in Murine CT26 Colon Carcinoma.

Authors:  Johanne Seguin; Bich-Thuy Doan; Heldmuth Latorre Ossa; Lauriane Jugé; Jean-Luc Gennisson; Mickaël Tanter; Daniel Scherman; Guy G Chabot; Nathalie Mignet
Journal:  Int J Mol Imaging       Date:  2013-07-02

7.  Deterministic and Stochastic Study for a Microscopic Angiogenesis Model: Applications to the Lewis Lung Carcinoma.

Authors:  Marek Bodnar; Pilar Guerrero; Ruben Perez-Carrasco; Monika J Piotrowska
Journal:  PLoS One       Date:  2016-05-16       Impact factor: 3.240

8.  A transferrin-target magnetic/fluorescent dual-mode probe significantly enhances the diagnosis of non-small cell lung cancer.

Authors:  Jiali Cai; Bingxin Gu; Fengwen Cao; Shiyuan Liu
Journal:  Oncotarget       Date:  2016-06-28

9.  Comparison and evaluation of two RGD peptides labelled with 68Ga or 18F for PET imaging of angiogenesis in animal models of human glioblastoma or lung carcinoma.

Authors:  Claire Provost; Aurélie Prignon; Laura Rozenblum-Beddok; Quentin Bruyer; Sylvie Dumont; Fatiha Merabtene; Valérie Nataf; Cédric Bouteiller; Jean-Noël Talbot
Journal:  Oncotarget       Date:  2018-04-10

10.  Preparation of parenteral nanocrystal suspensions of etoposide from the excipient free dry state of the drug to enhance in vivo antitumoral properties.

Authors:  Brice Martin; Johanne Seguin; Maxime Annereau; Thomas Fleury; René Lai-Kuen; Giovanni Neri; Anita Lam; Marcel Bally; Nathalie Mignet; Yohann Corvis
Journal:  Sci Rep       Date:  2020-10-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.